Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.

Atul A DeodharCorine Miceli-RichardXenofon BaraliakosHelena Marzo-OrtegaDafna D GladmanRicardo BlancoAyan Das GuptaRuvie MartinJorge SafiBrian PorterAbhijit SheteJames Todd Rosenbaum

Published in: ACR open rheumatology (2020)

The incidence rate of uveitis in secukinumab-treated patients with active AS does not suggest an increased risk with secukinumab treatment.

Keyphrases

ankylosing spondylitis
data analysis
rheumatoid arthritis
disease activity
risk factors
systemic lupus erythematosus
randomized controlled trial
newly diagnosed
juvenile idiopathic arthritis
phase iii